Proteotype Diagnostics
Organization
Grants and prizes
HORIZON-TMA-MSCA-DN, Hereditary and Early onset breast cancer: Comprehensive personalized Assessment, early Risk Evaluation, and clinical management, 101227105, €348.7k, 2026–2029, Jul 8, 2025
Grant for R&D, Analytical validation, pre-approval revenue, and business development for next-generation Multi Cancer Early Detection assay, 10136778, £75k, 2024–2025, Dec 1, 2024
Collaborative R&D, Urine-based "MCED At Home" test using amino acid biomarkers already validated in plasma, 10112443, £100k, 2024, May 1, 2024
Sources: cordis.europa.eu, gtr.ukri.org